HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1

Andrea Kovacs, Linda S. Chan, Zhi Chun Chen, William A. Meyer, Laila Muderspach, Mary Young, Kathryn Anastos, Alexandra M. Levine

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

To assess antiretroviral therapy, all compartments, including the genital tract, need to be evaluated. HIV-1 RNA was quantified in whole cervicovaginal lavage fluid (CVL) and plasma of 56 women and in the cellular and supernatant fractions of 27 of these women. Overall, we detected HIV-1 RNA in 59% of whole CVL samples and in 61% and 44% of cellular and supernatant fractions of the subset of women, respectively. Detectability of HIV-1 RNA in CVL increased with increasing level of plasma RNA in both unfractionated and cell-associated CVL components (p = .0004 and .002, respectively), but not in the cell-free fraction (p = .29). Mean HIV-1 RNA levels in CVL increased with decreasing CD4 counts (p = .002,) and with increasing plasma HIV-1 RNA (p < .001). Adjusted odds ratios (OR) for detectable CVL RNA were highest for women with CD4 counts <200 cells/mm3 (OR, 10.1; 95% confidence interval [CI]: 1.6-82.7; p = .02) and >50,000 copies/ml of plasma RNA (OR, 25.2; 95% CI, 3.2-554; p = .01). Treatment did not seem to affect RNA detection in CVL after adjusting for plasma RNA and CD4. In conclusion, we found that detectability and level of CVL RNA were closely associated with the cellular fraction of genital secretions in women and strongly correlated with the level of plasma RNA and CD4. Genital tract secretions may need to be tested in the assessment of treatment efficacy and this can easily be accomplished with this rapid and easy procedure using whole CVL.

Original languageEnglish (US)
Pages (from-to)124-131
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume22
Issue number2
StatePublished - Oct 1 1999
Externally publishedYes

Fingerprint

HIV-1
Therapeutic Irrigation
RNA
CD4 Lymphocyte Count
Therapeutics

Keywords

  • Genital tract
  • HIV
  • RNA
  • Women

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Kovacs, A., Chan, L. S., Chen, Z. C., Meyer, W. A., Muderspach, L., Young, M., ... Levine, A. M. (1999). HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 22(2), 124-131.

HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1. / Kovacs, Andrea; Chan, Linda S.; Chen, Zhi Chun; Meyer, William A.; Muderspach, Laila; Young, Mary; Anastos, Kathryn; Levine, Alexandra M.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 22, No. 2, 01.10.1999, p. 124-131.

Research output: Contribution to journalArticle

Kovacs, A, Chan, LS, Chen, ZC, Meyer, WA, Muderspach, L, Young, M, Anastos, K & Levine, AM 1999, 'HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 22, no. 2, pp. 124-131.
Kovacs, Andrea ; Chan, Linda S. ; Chen, Zhi Chun ; Meyer, William A. ; Muderspach, Laila ; Young, Mary ; Anastos, Kathryn ; Levine, Alexandra M. / HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1. In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1999 ; Vol. 22, No. 2. pp. 124-131.
@article{dd67dc28097c45dc893a8be428019866,
title = "HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1",
abstract = "To assess antiretroviral therapy, all compartments, including the genital tract, need to be evaluated. HIV-1 RNA was quantified in whole cervicovaginal lavage fluid (CVL) and plasma of 56 women and in the cellular and supernatant fractions of 27 of these women. Overall, we detected HIV-1 RNA in 59{\%} of whole CVL samples and in 61{\%} and 44{\%} of cellular and supernatant fractions of the subset of women, respectively. Detectability of HIV-1 RNA in CVL increased with increasing level of plasma RNA in both unfractionated and cell-associated CVL components (p = .0004 and .002, respectively), but not in the cell-free fraction (p = .29). Mean HIV-1 RNA levels in CVL increased with decreasing CD4 counts (p = .002,) and with increasing plasma HIV-1 RNA (p < .001). Adjusted odds ratios (OR) for detectable CVL RNA were highest for women with CD4 counts <200 cells/mm3 (OR, 10.1; 95{\%} confidence interval [CI]: 1.6-82.7; p = .02) and >50,000 copies/ml of plasma RNA (OR, 25.2; 95{\%} CI, 3.2-554; p = .01). Treatment did not seem to affect RNA detection in CVL after adjusting for plasma RNA and CD4. In conclusion, we found that detectability and level of CVL RNA were closely associated with the cellular fraction of genital secretions in women and strongly correlated with the level of plasma RNA and CD4. Genital tract secretions may need to be tested in the assessment of treatment efficacy and this can easily be accomplished with this rapid and easy procedure using whole CVL.",
keywords = "Genital tract, HIV, RNA, Women",
author = "Andrea Kovacs and Chan, {Linda S.} and Chen, {Zhi Chun} and Meyer, {William A.} and Laila Muderspach and Mary Young and Kathryn Anastos and Levine, {Alexandra M.}",
year = "1999",
month = "10",
day = "1",
language = "English (US)",
volume = "22",
pages = "124--131",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - HIV-1 RNA in plasma and genital tract secretions in women infected with HIV-1

AU - Kovacs, Andrea

AU - Chan, Linda S.

AU - Chen, Zhi Chun

AU - Meyer, William A.

AU - Muderspach, Laila

AU - Young, Mary

AU - Anastos, Kathryn

AU - Levine, Alexandra M.

PY - 1999/10/1

Y1 - 1999/10/1

N2 - To assess antiretroviral therapy, all compartments, including the genital tract, need to be evaluated. HIV-1 RNA was quantified in whole cervicovaginal lavage fluid (CVL) and plasma of 56 women and in the cellular and supernatant fractions of 27 of these women. Overall, we detected HIV-1 RNA in 59% of whole CVL samples and in 61% and 44% of cellular and supernatant fractions of the subset of women, respectively. Detectability of HIV-1 RNA in CVL increased with increasing level of plasma RNA in both unfractionated and cell-associated CVL components (p = .0004 and .002, respectively), but not in the cell-free fraction (p = .29). Mean HIV-1 RNA levels in CVL increased with decreasing CD4 counts (p = .002,) and with increasing plasma HIV-1 RNA (p < .001). Adjusted odds ratios (OR) for detectable CVL RNA were highest for women with CD4 counts <200 cells/mm3 (OR, 10.1; 95% confidence interval [CI]: 1.6-82.7; p = .02) and >50,000 copies/ml of plasma RNA (OR, 25.2; 95% CI, 3.2-554; p = .01). Treatment did not seem to affect RNA detection in CVL after adjusting for plasma RNA and CD4. In conclusion, we found that detectability and level of CVL RNA were closely associated with the cellular fraction of genital secretions in women and strongly correlated with the level of plasma RNA and CD4. Genital tract secretions may need to be tested in the assessment of treatment efficacy and this can easily be accomplished with this rapid and easy procedure using whole CVL.

AB - To assess antiretroviral therapy, all compartments, including the genital tract, need to be evaluated. HIV-1 RNA was quantified in whole cervicovaginal lavage fluid (CVL) and plasma of 56 women and in the cellular and supernatant fractions of 27 of these women. Overall, we detected HIV-1 RNA in 59% of whole CVL samples and in 61% and 44% of cellular and supernatant fractions of the subset of women, respectively. Detectability of HIV-1 RNA in CVL increased with increasing level of plasma RNA in both unfractionated and cell-associated CVL components (p = .0004 and .002, respectively), but not in the cell-free fraction (p = .29). Mean HIV-1 RNA levels in CVL increased with decreasing CD4 counts (p = .002,) and with increasing plasma HIV-1 RNA (p < .001). Adjusted odds ratios (OR) for detectable CVL RNA were highest for women with CD4 counts <200 cells/mm3 (OR, 10.1; 95% confidence interval [CI]: 1.6-82.7; p = .02) and >50,000 copies/ml of plasma RNA (OR, 25.2; 95% CI, 3.2-554; p = .01). Treatment did not seem to affect RNA detection in CVL after adjusting for plasma RNA and CD4. In conclusion, we found that detectability and level of CVL RNA were closely associated with the cellular fraction of genital secretions in women and strongly correlated with the level of plasma RNA and CD4. Genital tract secretions may need to be tested in the assessment of treatment efficacy and this can easily be accomplished with this rapid and easy procedure using whole CVL.

KW - Genital tract

KW - HIV

KW - RNA

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=0032707669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032707669&partnerID=8YFLogxK

M3 - Article

C2 - 10843525

AN - SCOPUS:0032707669

VL - 22

SP - 124

EP - 131

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -